An interventional study of Selective C-reactive protein apheresis (PentraSorb®-CRP) and Standard of care in Cardiogenic Shock and Acute Myocardial Infarction (AMI), sponsored by Leipzig Heart Science gGmbH. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Leipzig Heart Science gGmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 12th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 34th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:
University Hospital of Cologne · Sites in Germany
Ages 18–77
4TEEN4 Pharmaceuticals GmbH · Sites in Germany, Armenia, Belgium and 6 more countries
Ages 18–80
Abiomed Inc. · Sites in Germany, Italy, Switzerland
Ages 18+
University Heart Center Freiburg - Bad Krozingen · Sites in Germany
Ages 18+
Universität Münster · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 1 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 60 across the 22 interventional studies, 138 across the 14 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
Leipzig Heart Science gGmbH is the lead sponsor of 8 studies on the registry; 7 are open to participants now.
Leipzig Heart Science gGmbH has 2 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
4 of the studies in Shock, Cardiogenic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT068327224TEEN4 Pharmaceuticals GmbHA Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. | 2026-12-30 |
| NCT06308055Abiomed Inc.Abiomed Impella RT-DAQ - Observational Study | 2027-06-30 |
| NCT07515508University Heart Center Freiburg - Bad KrozingenMultimodal Phenotyping In Patients Referred With Acute Cardiac faiLurE | 2027-07-31 |
| NCT07687017Leipzig Heart Science gGmbHCRP Apheresis in Infarct-Related Cardiogenic Shock | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Shock, Cardiogenic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiogenic shock complicating acute myocardial infarction remains associated with high short-term mortality despite guideline-directed therapy. Systemic inflammation, particularly elevated C-reactive protein (CRP), may contribute to ongoing myocardial injury and organ dysfunction.
The CRP-SHOCK trial is an investigator-initiated, prospective, randomized, open-label, multicenter pilot study evaluating selective CRP apheresis as an adjunct to standard of care in patients with infarct-related cardiogenic shock. Patients are randomized to receive either standard therapy alone or standard therapy plus selective CRP apheresis using the PentraSorb®-CRP system.
The primary objective is to assess the effect of CRP apheresis on the CLIP score at 66 ± 8 hours after randomization. Secondary objectives include clinical outcomes, inflammatory biomarkers, and safety endpoints.
Cardiogenic shock following acute myocardial infarction is associated with a high inflammatory response and mortality rates of approximately 40-50% despite early revascularization and intensive care treatment. Experimental and clinical evidence suggests that elevated C-reactive protein (CRP) contributes to myocardial injury, impaired tissue regeneration, and adverse outcomes.
The CRP-SHOCK trial investigates whether selective removal of circulating CRP by apheresis improves short-term risk stratification and clinical outcomes in patients with infarct-related cardiogenic shock. The intervention consists of up to three CRP apheresis sessions initiated within 5 ± 1 hours after randomization and repeated at predefined intervals using the PentraSorb®-CRP system.
The primary efficacy endpoint is the CLIP score at 66 ± 8 hours after randomization. Secondary endpoints include mortality, major adverse cardiovascular events, biomarkers of inflammation and organ function, and safety outcomes such as bleeding, stroke, and infections. The trial is conducted as a multicenter pilot study in Germany and Austria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive standard of care for infarct-related cardiogenic shock plus selective C-reactive protein (CRP) apheresis using the PentraSorb®-CRP system. CRP apheresis is initiated within 5 ± 1 hours after randomization and repeated at 30 ± 4 hours and 54 ± 6 hours after randomization.
Device: Selective C-reactive protein apheresis (PentraSorb®-CRP) · Other: Standard of care
Participants receive guideline-directed standard of care for infarct-related cardiogenic shock without CRP apheresis.
Other: Standard of care
Selective removal of circulating C-reactive protein using the PentraSorb®-CRP adsorber system as an adjunct to guideline-directed standard of care.
Also known as: CRP Apheresis plus Standard of Care
Guideline-directed medical and interventional treatment for cardiogenic shock complicating acute myocardial infarction.
CLIP score
The CLIP score (Cystatin C, Lactate, Interleukin-6 and N-terminal pro B-type natriuretic peptide \[NT-proBNP\] score) is a biomarker-based risk score for predicting 30-day mortality in cardiogenic shock complicating acute myocardial infarction. It is calculated via a logistic regression model using the four biomarkers (Cystatin C, Lactate, Interleukin-6, and NT-proBNP), yielding a probability score ranging from 0 to 1 (or 0% to 100% when multiplied by 100). Higher scores indicate a higher probability of 30-day mortality, i.e., a worse outcome.
Time frame: 66 ± 8 hours after randomization
Major adverse cardiovascular events (MACE)
Composite endpoint of cardiovascular death, non-fatal myocardial infarction, or re-admission for heart failure.
Time frame: 30 days
All-cause mortality
Death from any cause within 30 days after randomization.
Time frame: 30 days
Cardiovascular mortality
Death due to cardiovascular causes within 30 days after randomization.
Time frame: 30 days
CLIP score over time
The CLIP score (Cystatin C, Lactate, Interleukin-6 and N-terminal pro B-type natriuretic peptide \[NT-proBNP\] score) is a biomarker-based risk score for predicting 30-day mortality in cardiogenic shock complicating acute myocardial infarction. It is calculated via a logistic regression model using the four biomarkers (Cystatin C, Lactate, Interleukin-6, and NT-proBNP), yielding a probability score ranging from 0 to 1 (or 0% to 100% when multiplied by 100). Higher scores indicate a higher probability of 30-day mortality, i.e., a worse outcome.
Time frame: 18 ± 4 hours, 42 ± 6 hours, and 66 ± 8 hours after randomization
Individual components of the CLIP score
The CLIP score (Cystatin C, Lactate, Interleukin-6 and N-terminal pro B-type natriuretic peptide \[NT-proBNP\] score) is a biomarker-based risk score for predicting 30-day mortality in cardiogenic shock complicating acute myocardial infarction. It is calculated via a logistic regression model using the four biomarkers (Cystatin C, Lactate, Interleukin-6, and NT-proBNP), yielding a probability score ranging from 0 to 1 (or 0% to 100% when multiplied by 100). Higher scores indicate a higher probability of 30-day mortality, i.e., a worse outcome.
Time frame: 18 ± 4 hours, 42 ± 6 hours, and 66 ± 8 hours after randomization
C-reactive protein (CRP) concentration
Serum CRP concentrations measured before and after CRP apheresis sessions.
Time frame: 9 ± 1 hours, 34 ± 4 hours, 58 ± 6 hours, and 66 ± 8 hours after randomization
Peak NT-proBNP concentration
Maximum NT-proBNP serum concentration recorded during the index hospital stay.
Time frame: During index hospitalization
Peak serum creatinine concentration
Maximum serum creatinine concentration recorded during the index hospital stay.
Time frame: During index hospitalization
Cardiac power index
The Cardiac Power Index (CPI) is a continuous hemodynamic measurement reflecting the rate of cardiac energy output indexed to body surface area, calculated as cardiac index × mean arterial pressure × a constant (W/m²). It is not a score on a defined scale but a continuous physiological parameter without fixed minimum or maximum values. Normal values are generally reported in the range of 0.5-0.7 W/m². Lower CPI values are associated with worse outcomes, including higher mortality, need for cardiac transplantation, or ventricular assist device placement - thus, higher values indicate better cardiac performance.
Time frame: 18 ± 4 hours, 42 ± 6 hours, and 66 ± 8 hours after randomization
Time to hemodynamic stabilization
Time from randomization to sustained hemodynamic stabilization as defined by the treating physician.
Time frame: hospital discharge
Duration of catecholamine therapy
Total duration of vasopressor and inotropic support.
Time frame: hospital discharge
Length of intensive care unit stay
Number of days spent in the intensive care unit.
Time frame: hospital discharge
Length of hospital stay
Total length of hospital stay in days.
Time frame: hospital discharge
Plan to share: No — Individual participant data (IPD) will not be shared publicly. Access to de-identified data may be considered upon reasonable request and subject to approval by the study sponsor and applicable ethics committees.
Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.
Of 48 non-industry interventional studies with no phase under Shock, Cardiogenic, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 11 months is below that.
Counting every sponsor, half of 52 studies reached it within 39 months; a quarter within 24 and three quarters within 55.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leipzig Heart Science gGmbH